Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape

Aruni Ghose; Patricia Lapitan; Vedika Apte; Adheesh Ghosh; Abhinav Kandala; Sreejana Basu; Jo Parkes; Sayali D Shinde; Stergios Boussios; Anand Sharma; Prantik Das; Nikhil Vasdev; Sara E Rebuzzi; Yüksel Ürün; Ravindran Kanesvaran; Akash Maniam; Giuseppe L Banna

doi:10.1007/s11912-024-01524-7

Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape

Aruni Ghose, Patricia Lapitan, Vedika Apte, Adheesh Ghosh, Abhinav Kandala, Sreejana Basu, Jo Parkes, Sayali D Shinde, Stergios Boussios, Anand Sharma, Prantik Das, Nikhil Vasdev, Sara E Rebuzzi, Yüksel Ürün, Ravindran Kanesvaran, Akash Maniam, Giuseppe L Banna

Research output: Contribution to journal › Review article › peer-review

Abstract

Purpose of Review
Our review delves into the progress across urological malignancies and discusses ongoing challenges and future directions in antibody–drug conjugate (ADC) development, emphasising their transformative potential in cancer care.

Recent Findings
ADCs have advanced from hematologic to solid tumours, notably in breast cancer, and are now pivotal in metastatic urological cancers as both monotherapies and in combination regimens, underscored by the FDA’s approval of enfortumab vedotin and sacituzumab govitecan for metastatic urothelial cancer. Progress in metastatic prostate cancer, particularly with ADCs targeting PSMA and STEAP1, is noteworthy, although renal cell cancer presents ongoing challenges. There is a continual search for agents in the metastatic, relapsed testicular cancer landscape.

Summary
ADCs have emerged as a pivotal innovation in oncology, blending targeted antibody therapy with potent cytotoxic drugs, significantly advancing treatment options for urological malignancies.

Original language	English
Journal	Current Oncology Reports
Early online date	23 Apr 2024
DOIs	https://doi.org/10.1007/s11912-024-01524-7
Publication status	E-pub ahead of print - 23 Apr 2024

Keywords

Antibody drug conjugate
Cancer
Chemotherapy
Prostate
Renal
Testicular
Urology
Urothelial

Access to Document

10.1007/s11912-024-01524-7Licence: Unspecified

Cite this

Ghose, A., Lapitan, P., Apte, V., Ghosh, A., Kandala, A., Basu, S., Parkes, J., Shinde, S. D., Boussios, S., Sharma, A., Das, P., Vasdev, N., Rebuzzi, S. E., Ürün, Y., Kanesvaran, R., Maniam, A., & Banna, G. L. (2024). Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape. Current Oncology Reports. Advance online publication. https://doi.org/10.1007/s11912-024-01524-7

@article{20f503013ea14d7e8d9da0aa1b502713,

title = "Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape",

abstract = "Purpose of ReviewOur review delves into the progress across urological malignancies and discusses ongoing challenges and future directions in antibody–drug conjugate (ADC) development, emphasising their transformative potential in cancer care.Recent FindingsADCs have advanced from hematologic to solid tumours, notably in breast cancer, and are now pivotal in metastatic urological cancers as both monotherapies and in combination regimens, underscored by the FDA{\textquoteright}s approval of enfortumab vedotin and sacituzumab govitecan for metastatic urothelial cancer. Progress in metastatic prostate cancer, particularly with ADCs targeting PSMA and STEAP1, is noteworthy, although renal cell cancer presents ongoing challenges. There is a continual search for agents in the metastatic, relapsed testicular cancer landscape.SummaryADCs have emerged as a pivotal innovation in oncology, blending targeted antibody therapy with potent cytotoxic drugs, significantly advancing treatment options for urological malignancies.",

keywords = "Antibody drug conjugate, Cancer, Chemotherapy, Prostate, Renal, Testicular, Urology, Urothelial",

author = "Aruni Ghose and Patricia Lapitan and Vedika Apte and Adheesh Ghosh and Abhinav Kandala and Sreejana Basu and Jo Parkes and Shinde, {Sayali D} and Stergios Boussios and Anand Sharma and Prantik Das and Nikhil Vasdev and Rebuzzi, {Sara E} and Y{\"u}ksel {\"U}r{\"u}n and Ravindran Kanesvaran and Akash Maniam and Banna, {Giuseppe L}",

note = "{\textcopyright} 2024, The Author(s), under exclusive licence to Springer Science Business Media, LLC, part of Springer Nature. This is the accepted manuscript version of a review article which has been published in final form at https://doi.org/10.1007/s11912-024-01524-7",

year = "2024",

month = apr,

day = "23",

doi = "10.1007/s11912-024-01524-7",

language = "English",

journal = "Current Oncology Reports",

issn = "1523-3790",

publisher = "Springer Nature Link",

}

TY - JOUR

T1 - Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape

AU - Ghose, Aruni

AU - Lapitan, Patricia

AU - Apte, Vedika

AU - Ghosh, Adheesh

AU - Kandala, Abhinav

AU - Basu, Sreejana

AU - Parkes, Jo

AU - Shinde, Sayali D

AU - Boussios, Stergios

AU - Sharma, Anand

AU - Das, Prantik

AU - Vasdev, Nikhil

AU - Rebuzzi, Sara E

AU - Ürün, Yüksel

AU - Kanesvaran, Ravindran

AU - Maniam, Akash

AU - Banna, Giuseppe L

N1 - © 2024, The Author(s), under exclusive licence to Springer Science Business Media, LLC, part of Springer Nature. This is the accepted manuscript version of a review article which has been published in final form at https://doi.org/10.1007/s11912-024-01524-7

PY - 2024/4/23

Y1 - 2024/4/23

N2 - Purpose of ReviewOur review delves into the progress across urological malignancies and discusses ongoing challenges and future directions in antibody–drug conjugate (ADC) development, emphasising their transformative potential in cancer care.Recent FindingsADCs have advanced from hematologic to solid tumours, notably in breast cancer, and are now pivotal in metastatic urological cancers as both monotherapies and in combination regimens, underscored by the FDA’s approval of enfortumab vedotin and sacituzumab govitecan for metastatic urothelial cancer. Progress in metastatic prostate cancer, particularly with ADCs targeting PSMA and STEAP1, is noteworthy, although renal cell cancer presents ongoing challenges. There is a continual search for agents in the metastatic, relapsed testicular cancer landscape.SummaryADCs have emerged as a pivotal innovation in oncology, blending targeted antibody therapy with potent cytotoxic drugs, significantly advancing treatment options for urological malignancies.

AB - Purpose of ReviewOur review delves into the progress across urological malignancies and discusses ongoing challenges and future directions in antibody–drug conjugate (ADC) development, emphasising their transformative potential in cancer care.Recent FindingsADCs have advanced from hematologic to solid tumours, notably in breast cancer, and are now pivotal in metastatic urological cancers as both monotherapies and in combination regimens, underscored by the FDA’s approval of enfortumab vedotin and sacituzumab govitecan for metastatic urothelial cancer. Progress in metastatic prostate cancer, particularly with ADCs targeting PSMA and STEAP1, is noteworthy, although renal cell cancer presents ongoing challenges. There is a continual search for agents in the metastatic, relapsed testicular cancer landscape.SummaryADCs have emerged as a pivotal innovation in oncology, blending targeted antibody therapy with potent cytotoxic drugs, significantly advancing treatment options for urological malignancies.

KW - Antibody drug conjugate

KW - Cancer

KW - Chemotherapy

KW - Prostate

KW - Renal

KW - Testicular

KW - Urology

KW - Urothelial

UR - http://www.scopus.com/inward/record.url?scp=85191055734&partnerID=8YFLogxK

U2 - 10.1007/s11912-024-01524-7

DO - 10.1007/s11912-024-01524-7

M3 - Review article

SN - 1523-3790

JO - Current Oncology Reports

JF - Current Oncology Reports

ER -

Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape

Abstract

Keywords

Access to Document

Other files and links

Embargoed Document

Fingerprint

Cite this